Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant Tuberculosis

RATIONALE: Current recommendations for the treatment of rifampicin- and multidrug-resistant tuberculosis include bedaquiline (BDQ) used for 6 months or longer. Evidence is needed to inform the optimal duration of BDQ. OBJECTIVES: We emulated a target trial to estimate the effect of three BDQ duratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Trevisi, Letizia, Hernán, Miguel A., Mitnick, Carole D., Khan, Uzma, Seung, Kwonjune J., Rich, Michael L., Bastard, Mathieu, Huerga, Helena, Melikyan, Nara, Atwood, Sidney A., Avaliani, Zaza, Llanos, Felix, Manzur-ul-Alam, Mohammad, Zarli, Khin, Binegdie, Amsalu Bekele, Adnan, Sana, Melikyan, Arusyak, Gelin, Alain, Isani, Afshan K., Vetushko, Dmitry, Daugarina, Zhenisgul, Nkundanyirazo, Patrick, Putri, Fauziah Asnely, Vilbrun, Charles, Khan, Munira, Hewison, Catherine, Khan, Palwasha Y., Franke, Molly F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Thoracic Society 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10263131/
https://www.ncbi.nlm.nih.gov/pubmed/36802336
http://dx.doi.org/10.1164/rccm.202211-2125OC

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10263131/
https://www.ncbi.nlm.nih.gov/pubmed/36802336
http://dx.doi.org/10.1164/rccm.202211-2125OC

Ejemplares similares